5-Amino-1MQ 50
$220.00
Iron Ascension 5-Amino-1MQ 50 is an advanced small-molecule selective NNMT (Nicotinamide N-methyltransferase) inhibitor engineered to optimize cellular energy dynamics, accelerate lipid oxidation, and preserve lean muscle tissue. By preventing the depletion of intracellular NAD+ and SAM (S-adenosylmethionine), it drives mitochondrial efficiency, enhances fat loss, and supports metabolic longevity without central nervous system stimulation.
Guaranteed safe checkout
Description
Description
Iron Ascension 5-Amino-1MQ 50
Specifications & Composition
| Specification | Details |
|---|---|
| Active Compound | 5-Amino-1-methylquinolinium (5-Amino-1MQ; chemical identity requires confirmation) |
| Concentration | 50 mg per tablet |
| Total Quantity | 60 tablets |
| Delivery System | Oral administration |
| Formulation Standard | Pharmaceutical grade (manufacturer claim; verification required) |
| Batch Testing | High-Performance Liquid Chromatography (HPLC), as reported |
Key Research Features
- NNMT Inhibition: 5-Amino-1MQ is an experimental compound investigated for its ability to inhibit nicotinamide N-methyltransferase (NNMT). Preclinical research has explored possible effects on cellular metabolism and adipose tissue; established clinical weight-loss efficacy in humans has not been demonstrated.
- NAD+ and SAM Pathways: NNMT participates in nicotinamide and S-adenosylmethionine (SAM) metabolism. Inhibition may influence these pathways in experimental models, but claims of reliably increasing NAD+, mitochondrial respiration, or ATP production in humans remain unproven.
- Non-Stimulant Profile: The compound is not established as a conventional stimulant. However, the absence of stimulant-like activity does not demonstrate cardiovascular safety, long-term tolerability, or freedom from other adverse effects.
Important Safety & Evidence Considerations
5-Amino-1MQ remains an investigational compound rather than an established, approved treatment for obesity or metabolic disease. Human safety, effective oral exposure, long-term effects, and potential drug interactions are not adequately established. It should not be marketed as a clinically proven fat-loss product or as a validated method of increasing NAD+ or ATP.
Quality Control & Lab Verification
| Quality Parameter | Reported Result |
|---|---|
| Compound | 5-Amino-1-methylquinolinium (oral tablets; identity requires confirmation) |
| Assay Result | 99.6% active compound (reported) |
| Testing Method | HPLC (reported) |
| Verification Status | PASSED (manufacturer-reported) |
Publication note: Confirm the exact chemical identity, structure, salt form, and nomenclature of the stated active ingredient before publication. Verify the 50 mg per tablet strength, 99.6% assay result, pharmaceutical-grade designation, and batch-specific HPLC certificate of analysis. HPLC assay alone does not establish identity conclusively, tablet uniformity, dissolution, contaminant absence, or clinical safety. Avoid presenting preclinical findings as proven human outcomes.
Specifications
- Short Stroke Gas Piston Gas System (Rifle Length)
- 18.6″ Barrel Length ( Mid-Weight style, non-fluted)
- 1:8 Twist Rate Rifling
Reviews
There are no reviews yet.